Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study

JF Byrne; C Healy; M Föcking; SR Susai; D Mongan; K Wynne; E Kodosaki; M Heurich; L de Haan; IB Hickie; S Smesny; A Thompson; C Markulev; AR Young; MR Schäfer; A Riecher-Rössler; N Mossaheb; G Berger; M Schlögelhofer; M Nordentoft; EYH Chen; S Verma; DH Nieman; SW Woods; BA Cornblatt; WS Stone; DH Mathalon; CE Bearden; KS Cadenhead; J Addington; EF Walker; TD Cannon; M Cannon; P McGorry; P Amminger; G Cagney; B Nelson; C Jeffries; D Perkins; DR Cotter

Journal article

Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study

JF Byrne, C Healy, M Föcking, SR Susai, D Mongan, K Wynne, E Kodosaki, M Heurich, L de Haan, IB Hickie, S Smesny, A Thompson, C Markulev, AR Young, MR Schäfer, A Riecher-Rössler, N Mossaheb, G Berger, M Schlögelhofer, M Nordentoft Show all

Schizophrenia Bulletin | OXFORD UNIV PRESS | Published : 2024

DOI: 10.1093/schbul/sbad184

Download PDF

Abstract

Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified us..

View full abstract

University of Melbourne Researchers

Andrew Thompson Author

Connie Markulev Author

Eric Yu Hai Chen Author

Patrick McGorry Author

Related Projects (1)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

Grants

Awarded by Stanley Medical Research Institute

Funding Acknowledgements

This research was supported by a Wellcome Flagship Innovations Award (IMPETUS-220438Z/20/Z). DRC and JFB are supported in part by Science Foundation Ireland (SFI) under Grant Number 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners. Research reported in this publication was supported by The Comprehensive Molecular Analytical Platform (CMAP) under The SFI Research Infrastructure Programme, reference 18/RI/5702. NAPLS2 and NAPLS3 were funded by the National Institute of Mental Health (NIMH). The NEURAPRO study was funded by grant 07TGF-1102 from the Stanley Medical Research Institute, grant 566529 from the National Health and Medical Research Council (NHMRC) Australia, and a grant from the Colonial Foundation.